Royal Philips' CEO Roy Jakobs reported an improved operational performance for the healthtech and personal health company in the second quarter of 2023 − the third in a row – with comparable sales growth of 9%. The improvement was generated across all divisions and regions, he said.
The buoyancy was tempered, as has been the case for two years, by the Respironics recall and Philips’ remediation action. Philips has put a new value creation plan in place, but the proposed US consent decree (CD) agreement and litigation and investigation by the US Department of Justice will consume much of the company’s attention for some time to come
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?